Drug
Apg 1252
Apg 1252: highest development phase Phase 1, developed by Ascentage Pharma Group Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ascentage Pharma Group Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| APG-1252 NCT04001777 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Apg 1252 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.